{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:53:19Z","timestamp":1777679599970,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105393","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:16:05Z","timestamp":1773771365000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug-Induced Subacute Cutaneous Lupus Secondary to Sulfasalazine"],"prefix":"10.7759","author":[{"given":"Kristal","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310370349","article-title":"Drug-induced subacute cutaneous lupus erythematosus","volume":"19","author":"Callen JP","year":"2010","unstructured":"Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010, 19:1107-11. 10.1177\/0961203310370349","journal-title":"Lupus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-1-49","article-title":"Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy","volume":"103","author":"Reed BR","year":"1985","unstructured":"Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985, 103:49-51. 10.7326\/0003-4819-103-1-49","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5070\/D3233034281","article-title":"An update in drug-induced subacute cutaneous lupus erythematosus","volume":"23","author":"Michaelis TC","year":"2017","unstructured":"Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017, 23:10.5070\/D3233034281","journal-title":"Dermatol Online J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-008-0890-x","article-title":"Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation","volume":"301","author":"Sontheimer RD","year":"2009","unstructured":"Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009, 301:65-70. 10.1007\/s00403-008-0890-x","journal-title":"Arch Dermatol Res"},{"key":"ref5","article-title":"Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease","volume":"77","author":"Carr-Locke DL","year":"1982","unstructured":"Carr-Locke DL. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease. Am J Gastroenterol. 1982, 77:614-6.","journal-title":"Am J Gastroenterol"},{"key":"ref6","article-title":"Sulfasalazine induced lupus in rheumatoid arthritis","volume":"21","author":"Caulier M","year":"1994","unstructured":"Caulier M, Dromer C, Andrieu V, Le Guennec P, Fournie B. Sulfasalazine induced lupus in rheumatoid arthritis. J Rheumatol. 1994, 21:750-1.","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.8.886","article-title":"Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA","volume":"39","author":"Gunnarsson I","year":"2000","unstructured":"Gunnarsson I, Nordmark B, Hassan Bakri A, et al.. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 2000, 39:886-93. 10.1093\/rheumatology\/39.8.886","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.1.104","article-title":"Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis","volume":"35","author":"Khattak FH","year":"1996","unstructured":"Khattak FH, Morris IM, Mattingly PC. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Br J Rheumatol. 1996, 35:104. 10.1093\/rheumatology\/35.1.104","journal-title":"Br J Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.2.175","article-title":"Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis","volume":"33","author":"Walker EM","year":"1994","unstructured":"Walker EM, Carty JE. Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis. Br J Rheumatol. 1994, 33:175-6. 10.1093\/rheumatology\/33.2.175","journal-title":"Br J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200089","article-title":"Sulphasalazine-induced systemic lupus erythematous in a patient with ankylosing spondylitis","volume":"21","author":"Tsai WC","year":"2002","unstructured":"Tsai WC, Chen CJ, Yen JH, Liu HW. Sulphasalazine-induced systemic lupus erythematous in a patient with ankylosing spondylitis. Clin Rheumatol. 2002, 21:339-40. 10.1007\/s100670200089","journal-title":"Clin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.5.288","article-title":"Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years","volume":"58","author":"Gordon MM","year":"1999","unstructured":"Gordon MM, Porter DR, Capell HA. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis. 1999, 58:288-90. 10.1136\/ard.58.5.288","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10110.x","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe GC","year":"2011","unstructured":"Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011, 164:465-72. 10.1111\/j.1365-2133.2010.10110.x","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.18.1993","article-title":"Antimicrobial photosensitive reactions","volume":"158","author":"Vassileva SG","year":"1998","unstructured":"Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. Arch Intern Med. 1998, 158:1993-2000. 10.1001\/archinte.158.18.1993","journal-title":"Arch Intern Med"},{"key":"ref14","unstructured":"Azulfidine. Sulfasalazine tablets. (2009). Accessed. December 8, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/007073s124lbl.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030060","article-title":"Drug hypersensitivity syndrome induced by sulfasalazine: a case report","volume":"101","author":"Chen DH","year":"2022","unstructured":"Chen DH, Zhou HR, Zhang YG, Shen GY, Xu C, Guan CL. Drug hypersensitivity syndrome induced by sulfasalazine: a case report. Medicine (Baltimore). 2022, 101:e30060. 10.1097\/MD.0000000000030060","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1140339","article-title":"Case report: sulfasalazine-induced hypersensitivity","volume":"10","author":"Kuchinskaya EM","year":"2023","unstructured":"Kuchinskaya EM, Chikova IA, Kostik MM. Case report: sulfasalazine-induced hypersensitivity. Front Med (Lausanne). 2023, 10:1140339. 10.3389\/fmed.2023.1140339","journal-title":"Front Med (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214598","article-title":"Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database","volume":"78","author":"Arnaud L","year":"2019","unstructured":"Arnaud L, Mertz P, Gavand PE, et al.. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019, 78:504-8. 10.1136\/annrheumdis-2018-214598","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449084-drug-induced-subacute-cutaneous-lupus-secondary-to-sulfasalazine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:16:06Z","timestamp":1773771366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449084-drug-induced-subacute-cutaneous-lupus-secondary-to-sulfasalazine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.105393","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}